The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a, Paragraph 8 of Book V of the Social Code for medicinal products containing the active ingredient combination olmesartan / amlodipine / HCT (ATC code according to WHO: C09DX03) within the framework of a so-called "open-house model". All interested and suitable pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V, subject to uniform conditions and a uniform access procedure. There is no exclusivity. The purchase quantity is unknown when the agreement is concluded and depends in particular on the demand from the insured, the development of the number of insured, the prescription behavior of the contract doctors and the dispensing and stocking behavior of the public pharmacies. The client does not guarantee any minimum purchase quantities.

For further information see point II.2.4) of the announcement.

The agreement can be concluded at any time and on the same terms. Individual contract negotiations are not carried out.

Interested pharmaceutical companies can request the participation documents (discount agreement, self-declaration that there are no grounds for exclusion, declaration of conformity) at the e-mail address mentioned under I.1). Agreements within the framework of this model are concluded between December 18, 2020 and January 31, 2023. Interested parties must submit the fully completed and signed participation documents (self-declaration that there are no grounds for exclusion, discount agreement in duplicate, declaration of conformity) for the first time by December 17, 2020, then by the 15th of a month, by post to the office named under I.1) . It depends on the access of both AOK Plus. If the 15th of a month falls on a Saturday, Sunday or national public holiday, the next working day will take the place of such a day. In the event of later receipt (after December 17th, 2020 or the 15th of a month), the submitted participation documents will be considered on the 15th of the following month.

The discount agreement comes into force as soon as AOK PLUS has signed the discount agreement after receipt of the complete and signed documents by the pharmaceutical company. The signing takes place until the end of the month in which the participation documents must have been received by AOK PLUS. Organizationally, AOK PLUS requires a preliminary run of around half a month to register the discount agreement. The initial labeling of discount medicinal products in the pharmacy software takes place from the second month following the receipt period for the participation documents. This time can vary if the deadlines for reporting dates on the nationwide AOK contract reporting portal DatRabatt are changed or re-established. A discount agreement is concluded with all pharmaceutical companies that meet the participation requirements and confirm this by signing the requested documents.

The contract ends no later than January 31, 2023, regardless of the date on which the contract was concluded. AOK Plus reserves the right to terminate the open-house procedure prematurely, especially in the case of the conclusion of exclusive discount agreements. In this case, the contracts already concluded will end in accordance with the contractual provisions. According to the experience of AOK Plus, exclusive discount agreements usually come into force 8 to 12 months after the publication of the corresponding announcement in the supplement to the Official Journal of the European Union. The future contractual partners in the open-house model are asked to regularly inform themselves about this in the supplement to the Official Journal of the European Union.